<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601416</url>
  </required_header>
  <id_info>
    <org_study_id>Xia Yunqiu</org_study_id>
    <nct_id>NCT03601416</nct_id>
  </id_info>
  <brief_title>Human Mesenchymal Stem Cells For Moderate and Severe Bronchopulmonary Dysplasia</brief_title>
  <official_title>Intravenous Human Umbilical-Cord-Derived Mesenchymal Stem Cells For Moderate and Severe Bronchopulmonary Dysplasias in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, single-center, dose escalation study to evaluate of safety and
      efficacy of human umbilical cord -derived mesenchymal stem cells (hUC-MSCs) in children with
      moderate and severe bronchopulmonary dysplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchopulmonary dysplasia (BPD) is one of the most common chronic lung diseases with poor
      prognosis, especially in preterm infants with moderate and severe BPD. However, there is lack
      of effective therapies for this disease.

      hUC-MSCs are widely used in clinic due to their low immunogenicity and convenient to get.Many
      animal study had shown that hUC-MSCs had therapeutic effects on a variety of animal models of
      lung disease.Furthermore,there are a large number of clinical trials of MSCs applied to
      various system diseases and the safety was verified.So,the main purpose of this study is to
      evaluate the safety and efficacy of hUC-MSCs in participants with moderate and severe
      bronchopulmonary dysplasia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the accumulative duration of oxygen therapy</measure>
    <time_frame>from the time of diagnosis to the time of stopping oxygen therapy</time_frame>
    <description>To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of blood pressure in participants</measure>
    <time_frame>24 hours after administration</time_frame>
    <description>To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia. Blood pressure is measured by electronic sphygmomanometer .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of heart rate in participants</measure>
    <time_frame>24 hours after administration</time_frame>
    <description>To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes of respiratory rate in participants</measure>
    <time_frame>24 hours after administration</time_frame>
    <description>To evaluate the safety of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of high-resolution chest CT in participants</measure>
    <time_frame>within 2 years after administration</time_frame>
    <description>To evaluate the safety and efficacy of human umbilical cord -derived mesenchymal stem cells for moderate and severe bronchopulmonary dysplasia.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Bronchopulmonary Dysplasia</condition>
  <arm_group>
    <arm_group_label>Transplantation of Mesenchymal Stem Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Transplantation of Mesenchymal Stem Cell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transplantation of mesenchymal stem cell</intervention_name>
    <description>Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.
Dose A - 1 million cells per kg Dose B - 5 million cells per kg</description>
    <arm_group_label>Transplantation of Mesenchymal Stem Cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No Transplantation of Mesenchymal Stem Cell</intervention_name>
    <description>Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.</description>
    <arm_group_label>No Transplantation of Mesenchymal Stem Cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participants with moderate and severe bronchopulmonary dysplasia are not well treated
             by routine therapy

          2. The legal representative or the participant had signed consent.

        Exclusion Criteria:

          -  1. Severe underlying diseases (e.g. systemic and hematological malignancies, heart
             failure, liver and kidney failure, immune deficiency, severe infectious diseases,
             III-IV grade pulmonary hypertension, Lung transplantation, current indications of
             acute surgery after lung transplantation) 2. Participants whose age is more than 1
             year old.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhou Fu</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunqiu Xia</last_name>
    <phone>023-63622066</phone>
    <email>sunny_199001@foxmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lin Zou</last_name>
    <phone>023-63622066</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yunqiu Xia</last_name>
      <phone>13637719980</phone>
      <email>sunny_199001@foxmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ahn SY, Chang YS, Kim JH, Sung SI, Park WS. Two-Year Follow-Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia. J Pediatr. 2017 Jun;185:49-54.e2. doi: 10.1016/j.jpeds.2017.02.061. Epub 2017 Mar 21.</citation>
    <PMID>28341525</PMID>
  </reference>
  <reference>
    <citation>Laube M, Stolzing A, Thome UH, Fabian C. Therapeutic potential of mesenchymal stem cells for pulmonary complications associated with preterm birth. Int J Biochem Cell Biol. 2016 May;74:18-32. doi: 10.1016/j.biocel.2016.02.023. Epub 2016 Feb 27. Review.</citation>
    <PMID>26928452</PMID>
  </reference>
  <reference>
    <citation>Hansmann G, Fernandez-Gonzalez A, Aslam M, Vitali SH, Martin T, Mitsialis SA, Kourembanas S. Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension. Pulm Circ. 2012 Apr-Jun;2(2):170-81. doi: 10.4103/2045-8932.97603.</citation>
    <PMID>22837858</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>January 11, 2019</last_update_submitted>
  <last_update_submitted_qc>January 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Xia Yunqiu</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <keyword>human umbilical cord -derived mesenchymal stem cells</keyword>
  <keyword>moderate and severe bronchopulmonary dysplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

